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BACKGROUND. A Phase II study of previously untreated patients with malignant low
grade follicular lymphoma given a combination of unlabeled tositumomab and
tositumomab labeled with iodine-131 has recently been completed. The responses
of these patients have been characterized, and for some of them tumor dosimetry
during therapy has been estimated not only by pretherapy tracer conjugate views
but also by a hybrid method.
METHODS. Available patients were studied if they had had a pelvic or abdominal
tumor evaluation by single photon emission computed tomography (SPECT) and
achieved a partial response. A tumor outlined on the iodine-131 conjugate-view
images was called a composite tumor. Its volume estimate came from multiple, not
necessarily contiguous, regions of interest (ROI) on the pretherapy computed
tomography (CT) scan. Its radiation dose was estimated from the weeklong series
of pretherapy images and standard Medical Internal Radiation Dose methods.
Computed tomography ROI were also grouped into smaller, contiguous volumes
that defined individual tumors. Their radiation doses were estimated by the hybrid
method. This method employed the activity measured for each individual tumor
by a single intratherapy SPECT scan, as well as the tumor’s volume, to individually
normalize the composite time-activity curve as appropriate. The individual nor-
malization factors then converted the composite radiation dose to radiation doses
for individual tumors. Reduction in tumor volume was calculated for both com-
posite and individual tumors at 12 weeks posttherapy.
RESULTS. For 14 composite tumors in 10 patients, the median pretherapy volume
was 170 cm3. Application of a sigmoidal curve function to the plot of volume
reduction versus radiation absorbed dose resulted in degeneration of the curve
into a straight line with a negative slope. There was no statistical significance in the
relationship (P  0.73). For 43 individual tumors, the median pretherapy tumor
volume was 26 cm3. The plot of volume reduction versus dose was fairly well fit by
a sigmoidal curve, and the relationship approached statistical significance (P
 0.06). The representation assigned 56% of the shrinkage to the effects of unla-
beled tositumomab. For the subset of individual tumors with a pretherapy volume
less than 10 cm3 from 6 patients (n  15), the relationship was significant (P
 0.03). The sigmoidal representation assigned only 12% of the shrinkage to
unlabeled tositumomab, as contrasted with 72% for tumors with pretherapy vol-
ume greater than 10 cm3.
CONCLUSIONS. For patients who attained a partial response, analysis of individual
tumors by a hybrid dosimetric method led to a dependence between volume
reduction at 12 weeks and radiation dose that tended to be significant. The same
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was not true with dosimetry of composite tumors based on pretherapy conjugate
views alone. It appeared that volume reductions from both unlabeled antibody and
radiation dose were important in tositumomab therapy of lymphoma patients,
with unlabeled antibody relatively more important for larger tumors. Cancer 2002;
94:1258 – 63. © 2002 American Cancer Society.
DOI 10.1002/cncr.10294
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Radioimmunotherapy of lymphoma patients withiodine-131 (131I) tositumomab has been under in-
vestigation at the University of Michigan Medical Cen-
ter for over 10 years. Details of the Phase I experience
with tositumomab at this center have been summa-
rized.1 A confirmatory, multicenter trial of chemother-
apy-relapsed/refractory low-grade and transformed
low-grade non-Hodgkin lymphoma (NHL) patients
has reported an overall response rate of 57% and a
complete response rate of 32%.2 Results from a re-
cently completed Phase II study of previously un-
treated low-grade NHL patients have also been pub-
lished.3,4 An abstract about this study has reported the
correspondence between degree of response and not
only radiation dose estimates from pretherapy conju-
gate views but also disease characteristics.5 For a sub-
set of these patients, an initial report on the corre-
spondence between degree of response and radiation
dose from a hybrid computed tomography–single
photon emission computed tomography (CT-SPECT)
conjugate-view method6 has also been published.7 In
the current article, we report an analysis of tumor
volume reduction in a subset of previously untreated
low-grade NHL patients who eventually attained a
partial response. For the patients, we estimated vol-
ume reduction of tumor at a single time point after
therapy, rather than at all time points at which CT
scans were taken. The results from the hybrid method
for individual tumors are compared with those from
conjugate views for composite tumors. The terms
composite and individual, as applied to tumors, are
defined.
PATIENTS AND METHODS
The two major criteria for entrance into the Phase II
study were that patients be 1) previously untreated,
and 2) diagnosed with malignant low-grade follicular
lymphoma.
Baseline Computed Tomography and Administered
Activity for Evaluation and Treatment
The patients received a baseline CT scan. This scan
was usually obtained sometime during the week prior
to the administration of a trace dose of 131I–labeled
tositumomab. Patients then underwent pretherapy
conjugate-view imaging with a tracer dose of 131I-
labeled tositumomab. In all cases, it was the first time
the patients were administered tositumomab and also
the first time they were undergoing an intervention for
their lymphoma. For the 1-week tracer evaluation,
patients were given a 450-mg predose of unlabeled
tositumomab infused over 1 hour to optimize biodis-
tribution and then an infusion of tositumomab la-
beled with about 185 MBq (5 mCi) of 131I. This evalu-
ation was then followed by the administration on Day
7 of a therapy dose. This dose consisted of an infusion
of the same amount of predose as used in the evalu-
ation, followed by the administration of a higher ac-
tivity of labeled tositumomab. This higher activity had
been calculated to give a 75-centigray (cGy) total-body
radiation absorbed dose based on the tracer measure-
ments. The patients also underwent intratherapy
SPECT imaging. The time point for the single scan was
usually between 2 and 3 days after the therapy admin-
istration.
Estimates of Tumor Volume and Radiation Dose
Disease involvement shown on the baseline CT scan
was documented by a radiologist (I. R. F.), who drew
regions of interest (ROI) outlining the cancerous
lymph nodes plane by plane.
A tumor outlined on the 131I conjugate-view im-
ages was called a composite tumor. Its volume esti-
mate came from multiple, not necessarily contiguous,
ROI on the baseline CT scan. The association of many
particular ROI into one composite tumor volume of
interest (VOI) was due to the projective nature of the
conjugate-view images and to the relatively poor res-
olution of the nuclear medicine camera-collimator
system. The CT ROI were also grouped into smaller
contiguous volumes that defined what were called
individual tumors. This grouping was accomplished
by the principal author using the CT image set, which
had higher resolution and was three-dimensional. The
criterion for starting an individual tumor was that the
included ROI had to touch in a given plane or had to
be in adjacent planes and overlap. Once an individual
tumor was started, another ROI touching at least one
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of its components or overlapping at least one of them
from an adjacent plane was also included as part of
the tumor. It was also possible for an individual tumor
to consist of a single ROI.
The dosimetry of the composite tumors from con-
jugate views was fairly standard; details of the method
have been summarized previously.6 Dosimetric esti-
mation for individual tumors with the hybrid method
depended on four features: 1) the baseline CT was
used to delineate the tumor boundary; 2) sequential
tracer conjugate views for a composite tumor were
used to estimate the shape of the therapy time-activity
curve; 3) an intratherapy SPECT was performed to set
the activity level for each tumor at that time point
during therapy; and 4) the dosimetric estimates for
individual tumors were obtained by appropriately
multiplying the conjugate-view radiation dose esti-
mate. The details of the method were given in two
recent publications.6,7
After therapy with tositumomab, the patients un-
derwent follow-up CT scans at 6, 12, and 25 weeks and
every 13 weeks thereafter, usually for 1 year and for up
to 2 years.
Choice of Patient and Time of Evaluation, and Criteria for
a Tumor Remnant
Because of limited resources, we could not evaluate all
the patients who had undergone a SPECT scan. Pre-
vious results indicated that abdominal and pelvic tu-
mors have similar dosimetry, with axilla tumors in a
different category due to either technical or, more
likely, physiologic causes.6 Since they had a greater
range in their dosimetric estimates, we chose to ana-
lyze the patients with abdominal and pelvic SPECT
scans. To reduce the numbers further, as well as to
have a more homogeneous group, we needed to ana-
lyze either the patients who eventually attained a
complete response (CR) or those with a partial re-
sponse (PR), classified by standard criteria. For the
analysis presented in this article, we have included
only those patients who eventually were classified as
having achieved a PR. The reasoning was that we
wanted to assure that at least some tumors had un-
dergone a volume reduction of less than 100%. Among
47 patients who underwent a SPECT scan covering the
abdomen or pelvis, 10 were classified as having
achieved a PR, and these were analyzed. An examina-
tion of the 37 CR patients in the future would also be
of interest.
To further conserve resources, we also chose to
evaluate tumor volume reduction from only the CT
scans taken at 12 weeks posttherapy, rather than at all
time points at which patients were evaluated. The
rationale for this particular choice was that all patients
had achieved their PR response status by this time. In
the future, investigation of the degree of volume re-
duction at earlier and/or later time points would also
be of interest. The same radiologist who evaluated the
baseline CT scans also evaluated the 12-week CT scans
and drew ROI for the remaining cancerous tissue.
These ROI were grouped into remnants for the com-
posite and for the individual tumors by the principal
author. To be part of a given tumor remnant, ROI had
to fall within the transverse and longitudinal extent of
the pretherapy tumor. However, ROI did not have to
meet the more stringent criteria for originally being
classified as an individual tumor.
Calculation of Volume Reduction and Fitting
The number of pixels in all ROI belonging to a tumor
or tumor remnant were summed. Volume was com-
puted by multiplying by the volume of a single voxel.
Percent volume reduction, R, was computed as fol-
lows:
R  100 
original volume  volume at 12 weeks
original volume
The data points for R versus radiation dose, D, were fit
by a probit function.8 This function is the sigmoidal
curve that is commonly used to represent dose-re-









x  a  b  D
Here, a and b were parameters to be returned by the
fitting. With this function, if the variable a has a large
negative value, then the curve has a sigmoidal shape
beginning at the origin. If the variable a is less nega-
tive, or positive, only part of the sigmoid is present
and there is a positive intercept, i.e., there is a positive
volume reduction even with zero radiation dose. This
latter case can represent a volume reduction from
unlabeled antibody. Choosing the probit function is
appropriate because it is already known that unla-
beled tositumomab, administered by itself, causes
lymphoma tumors to respond9 (Knox SJ, personal
communication).
RESULTS
For 10 PR patients, 14 composite tumors in the abdo-
men or pelvis were identified, had dose estimates
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based on conjugate views alone, and were evaluated
for volume reduction. The range in pretherapy volume
for these 14 composite tumors was 42 cm3 to 847 cm3.
The mean volume was 263  63 cm3 and the median
volume was 170 cm3. (The value after  is the stan-
dard error.) As seen from CT, a given composite tumor
was composed of 1–9 individual tumors. The probit fit
for the reduction-versus-dose data for composite tu-
mors degenerated into an almost-straight line with a
negative slope, as shown in Figure 1. There was no
statistical significance in the relationship (P  0.73).
The 14 composite tumors were comprised of a
total of 43 individual tumors. These individual tumors
had radiation dose estimates from hybrid CT intra-
therapy SPECT conjugate views. The range of pre-
therapy volume for these tumors was 2.0 cm3 to 847
cm3. The mean volume was 88  25 cm3 and the
median volume was 26 cm3. Volume reduction for
these 43 individual tumors, versus radiation dose, is
plotted in Figure 2. The data were fit by the probit
function, with a  0.141  0.403 and b  1.67  103
 1.3  103cGy1; the dependence tended toward a
significant level (P  0.06). Data points had consider-
able scatter about the returned function, possibly due
to experimental errors in the estimates of both radia-
tion dose and volume reduction. The Pearson corre-
lation coefficient (r) for R from the fit versus the mea-
sured R was 0.44. The volume-reduction intercept at
zero radiation dose was 55.6%. We interpreted this
value as the average fractional volume reduction at 12
weeks caused by the unlabeled tositumomab.
Furthermore, data for individual tumors were di-
vided into two subsets based on pretherapy tumor
volume. The probit fit for the 15 individual tumors
with pretherapy volume less than 10 cm3 distributed
over 6 patients is shown in Figure 3. The fit was quite
good. Compared with the relationship for tumors of all
volumes, the significance of the relationship increased
to P  0.029, the r value increased to 0.83, and the
amount of volume reduction ascribed to unlabeled
antibody decreased to only 11.6%.
Tumors in the subset with volume greater than 10
cm3 were not represented as well by the probit func-
tion, and the relationship was not significant at the 5%
level of confidence (P  0.307). Details of all four
analyses are given in Table 1.
DISCUSSION
The result for volume reduction versus radiation dose
from pretherapy conjugate views for composite tu-
FIGURE 1. This plot shows the percentage of volume reduction versus
radiation dose for 14 composite tumors. Radiation dose was estimated by
pretherapy tracer conjugate views alone. The line is best fit to the data by a
probit function. The usual sigmoidal shape for the function has degenerated
into an almost-straight line with a negative slope.
FIGURE 2. This plot shows the percentage of volume reduction versus
radiation dose for 43 individual tumors. Radiation dose was estimated by hybrid
computed tomography–single photo emission computed tomography conjugate
views. The line is best fit to the data by a probit function. Only the upper half
of the usual sigmoidal shape appears, because of a 55% volume reduction (see
positive intercept) with zero radiation dose, presumably due to unlabeled
antibody alone. Data points have considerable scatter about the fit, possibly
due to experimental error in the estimates of both radiation dose and volume
reduction.
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mors was much less satisfactory than that from hybrid
CT intratherapy SPECT conjugate views for individual
tumors. That is, it did not show the reduction to be
larger when the measured radiation dose was greater,
as expected. An obvious reason is the possibility for
cancerous lymph nodes that have different responses
to therapy to be combined into a single composite
tumor simply because of the accident of their align-
ment in an anterior-posterior projection. Another rea-
son might be the importance of sampling the tumor
activity during therapy rather than estimating it from
pretherapy scanning.
The overall rationale for the method used to esti-
mate dosimetry for the individual tumors by the hy-
brid method was as follows: 1) The use of sequential
tracer conjugate views saves the effort needed to ac-
quire and analyze a time sequence of SPECT image
sets. 2) The intratherapy SPECT may improve accu-
racy by employing SPECT and by having a measure-
ment during therapy. 3) The use of CT to outline the
tumor VOI for activity assessment increases resolution
compared with that available with SPECT, and even
more so compared with conjugate views. Relying on
CT for the outline does require a fusion of the CT
image set to the SPECT image set, however. 4) Indi-
vidual tumor dosimetry by multiplication of the com-
posite tumor dose by an appropriate factor reduces
effort. Some error in the gamma-ray component of the
radiation dose results, but this component is less than
5% of the total, and so the error is judged to be ac-
ceptable.
The current results from the hybrid method of
dosimetry need further verification. Perhaps the most
reliable result was that from all tumors, since it in-
volves the most data.
If the division into two subsets based on pre-
therapy volume yields two basically correct relation-
ships, a further conclusion is that cold tositumomab
has a greater effect relative to 131I-labeled tositu-
momab for tumors with initially larger volumes com-
pared with smaller volumes. This conclusion is sup-
ported by an argument based on accessibility. The
argument rests on a decreased likelihood that the en-
tire tumor volume will be irradiated if it is large. That
is, for the larger tumors, one assumes that only the
outer rim is accessible to the antibody for the 8-day
time period during which most radioactive decays
occur. The entire tumor is presumably accessible to
antibody by further diffusion after a period longer
than 8 days. Thus, radiation plays less of an overall
role, and the cold antibody, by default, plays a rela-
tively larger role. To make this argument, it helps to
assume that the residence time of cold antibody in the
tumor is longer than 8 days, which is unproven, al-
though certainly possible (the tumor residence time is
not necessarily equal to the blood residence time,
which is shorter than 8 days). The above argument is
supported by the observation that larger tumors ab-
sorb slightly less radiation than smaller tumors.6 If the
above argument is correct, the results reported are
indirect evidence that the tumor residence time for
tositumomab is longer than 8 days.
The time course of tumor volume reduction has
not been followed. Different tumors may shrink at
different rates. All patients had achieved their PR sta-
tus by the time of our evaluation at 12 weeks. Some or
all of the tumors may still have been shrinking, how-
ever. It is possible that all the evaluated tumors even-
tually reached 100% volume reduction. The patient
would still meet PR criteria if tumors in a body region
not scanned by SPECT remained. On the other hand,
by evaluating the CT images at other time points, it
may be possible to obtain a plateau value for the
greatest tumor volume reduction. A plot of this pla-
teau value versus radiation dose might yield a func-
tional fit with better adherence of individual values to
the fit. It might also be possible to establish an initial
FIGURE 3. This plot shows the percentage of volume reduction versus the
radiation dose for the 15 individual tumors evaluated by hybrid computed
tomography–single photon emission computed tomography conjugate views.
These tumors had a pretherapy volume of less than 10 g. The line is best fit
to the data by a probit function. Data points match the function quite well. Only
11% of the volume shrinkage (note positive intercept) is attributed to effects
from the unlabeled antibody for these small tumors. This shrinkage compares
with 71.6% for tumors with a volume greater than 10 g (data and fit not
shown).
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rate of shrinkage for the tumors. This rate itself may be
correlated to the radiation dose. These possibilities are
matters for future research.
The sample selection in which only partial re-
sponders were analyzed may affect our conclusions.
For previously untreated patients who underwent
tositumomab therapy, partial responders represented
less than 30% of all patients treated (the vast majority
were complete responders). To our knowledge, the
volume reduction of tumors in patients who eventu-
ally obtained a CR has not been investigated in a
similar analysis. According to standard criteria used to
define CR, these tumors all eventually reach 100%
volume reduction. However, at 12 weeks they may or
may not follow the same probit function as the tumors
in patients who achieve a PR. Again, this is a matter for
further research.
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TABLE 1
Dosimetric Method, Number of Tumors and Patients, and Results from Probit Fits




Hybrid CT SPECT conjugate views All (43 tumors, 10 patients) 0.056 0.44 55.6
Conjugate views All (14 tumors, 10 patients) 0.73 0.53 84.2
Hybrid CT SPECT conjugate views V  10 gm (28 tumors, 10 patients) 0.31 0.18 71.6
Hybrid CT SPECT conjugate views V  10 gm (15 tumors, 6 patients) 0.029 0.83 11.6
CT: computed tomography; SPECT: single photon emission computed tomography.
a P values are for the significance of the given relationship relative to no dose response relationship (i.e., a test of the probit equation with the chosen values of a and b relative to that equation with a  0 and b
 0, which is volume reduction  50% independent of dose).
b r value is the Pearson correlation coefficient for % volume reduction from fit vs. measured % volume reduction.
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